Jason Brett

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

John B. Buse, Julio Rosenstock, Giorgio Sesti et al. · The Lancet · 2009 · 1.5K citations

Medicine, Endocrinology, Pharmacology +13

Evidence Linking Hypoglycemic Events to an Increased Risk of Acute Cardiovascular Events in Patients With Type 2 Diabetes

Stephen S. Johnston, Christopher S. Conner, Mark Aagren et al. · Diabetes Care · 2011 · 188 citations · Full text

Medicine, Cardiology, Internal Medicine +16

Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials

John B. Buse, Alan J. Garber, Julio Rosenstock et al. · The Journal of Clinical Endocrinology & Metabolism · 2011 · 150 citations

Medicine, Immunology, Pharmacology +17

Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials

Patrick M. O’Neil, Vanita R. Aroda, Arne Astrup et al. · Diabetes Obesity and Metabolism · 2017 · 112 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Mild Renal Impairment and the Efficacy and Safety of Liraglutide

Jaime A. Davidson, Jason Brett, A Falahati et al. · Endocrine Practice · 2010 · 79 citations

Pharmacy, Nephrology, Pharmacotherapy +12